The latest biotech news

novartis avexis zolgensma fda data manipulation

News and Trends 2 Apr 2020

Update: FDA Imposes No Penalties for Novartis Data Manipulation Scandal

Update (02/04/2020): The FDA has concluded an investigation into a data manipulation scandal surrounding the approval of Novartis’ gene therapy Zolgensma, and has decided against sanctions. The FDA launched an investigation into the manipulated data surrounding the gene therapy application last year, and recently reported that the investigated data violations didn’t meet the threshold for […]

April 2, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 2 Apr 2020

Swiss and German Team to Develop Inhaled mRNA Coronavirus Treatment

The Swiss antibody specialist Neurimmune and the German RNA biotech Ethris are collaborating to develop inhaled messenger RNA (mRNA) antibodies that can treat the catastrophic respiratory effects of coronavirus disease, also known as Covid-19. The therapeutic mRNA would be delivered directly into the lungs of symptomatic patients via nebulizers with nanoparticle aerosols. The mRNA could […]

April 2, 2020 - 3 minutesmins - By Anita Chakraverty

News and Trends 31 Mar 2020

Ipsen Resumes Phase III Testing for Rare Disease Drug and Abandons Pediatric Trial

The French pharmaceutical company Ipsen has restarted the dosing of its treatment for a rare bone disease in a phase III trial after obtaining questionable interim results. At the same time, the company has terminated a phase II trial of the same drug in pediatric patients with a different bone disorder following a partial clinical […]

March 31, 2020 - 4 minutesmins - By Karen O’Hanlon Cohrt

News and Trends 31 Mar 2020

Swiss Biopharma Launches Second Cancer Antibody Deal with Japanese Pharma Giant

The Japanese heavyweight Ono Pharmaceutical has recruited Numab Therapeutics for a second time to co-develop a multi-specific antibody cancer treatment in a deal worth up to €246M (CHF 260M). The announcement follows a two-year collaboration between Ono and Numab announced in March 2017. Under the new agreement, which includes upfront and milestone payments, Ono has […]

March 31, 2020 - 3 minutesmins - By David Kirk

News and Trends 31 Mar 2020

Update: AM-Pharma Increases Acute Kidney Injury Phase III Funds to €163M

Update (31/03/2020): AM-Pharma has raised an extra €47M on top of an existing €116M equity round to fund an upcoming phase III trial of a treatment for acute kidney injury. The money will help the Dutch biotech to prepare for its upcoming phase III trial of a protein drug for acute kidney injury, which is […]

March 31, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 27 Mar 2020

Evox Therapeutics Receives up to €800M from Takeda To Tackle Rare Diseases

The Japanese pharmaceutical company Takeda has struck a deal worth up to €803M with UK biotech Evox Therapeutics to develop rare disease treatments delivered to cells via nanocapsules called exosomes. As part of the deal, Evox will use its proprietary technology platform to modify and load RNA and protein drugs into exosomes and target the […]

March 27, 2020 - 3 minutesmins - By Laura Cowen

News and Trends 26 Mar 2020

Silence Therapeutics to Work with AstraZeneca in RNAi Deal Worth up to €3.6B

AstraZeneca is recruiting RNAi specialist Silence Therapeutics to develop treatments for cardiovascular, renal, metabolic, and respiratory diseases. RNA interference, or RNAi, is a relatively new field of medicine in which therapeutic small interfering (si)RNA molecules — known as siRNA molecules — can selectively block genes and thus inhibit the production of disease-causing proteins. John Strafford, […]

March 26, 2020 - 3 minutesmins - By Laura Cowen

News and Trends 26 Mar 2020

Novacyt Launches Two-Hour Coronavirus Test After FDA Approval

The French clinical diagnostics specialist Novacyt has announced FDA authorization for its fast and easily transportable test for the coronavirus disease COVID-19. The company is also rolling out the kit this week via manufacturing and distribution partnerships across Europe. The test received an Emergency Use Authorization from the FDA, which means it can only be […]

March 26, 2020 - 3 minutesmins - By External Contributor

News and Trends 25 Mar 2020

DBV Technologies’ Peanut Allergy Treatment Hits FDA Setback

French biotech DBV Technologies’ bid for the US approval of a skin patch to treat nut allergies could be delayed as the FDA requested more information on the patch’s efficacy. Specifically, the FDA requested more information on patch-site adhesion – critical to the patch working effectively – as well as its long-term efficacy. According to […]

March 25, 2020 - 3 minutesmins - By External Contributor

alzheimers disease phase iii UK 1 e1557338331863

News and Trends 24 Mar 2020

Eli Lilly Sweetens AC Immune Alzheimer’s Treatment Deal by €38M

A deal between Swiss biotech AC Immune and Eli Lilly to develop an oral Alzheimer’s disease drug has increased in worth by €38M with a new milestone payment. AC Immune and Eli Lilly modified a deal signed in late 2018 to co-develop a small molecule treatment to slow the progression of Alzheimer’s disease. Specifically, the […]

March 24, 2020 - 3 minutesmins - By Jonathan Smith

moderna biontech personalized cancer vaccine

News and Trends 24 Mar 2020

Vaccitech’s Prostate Cancer Vaccine Shows Promise in Phase II

The UK immunotherapy company Vaccitech has announced promising initial results from a phase IIa trial of a therapeutic vaccine that could offer a new way to treat advanced prostate cancer. In the open-label trial, the University of Oxford spin-off enrolled 23 patients with advanced castration-resistant prostate cancer. The patients received the company’s viral vector vaccine […]

March 24, 2020 - 2 minutesmins - By Anita Chakraverty

News and Trends 23 Mar 2020

ViiV Healthcare’s Monthly HIV Injection Gains First Approval in Canada

A monthly two-drug injection developed by the GSK spinoff ViiV Healthcare has been approved for the treatment of HIV in Canada, which could replace the need for daily antiretroviral pills. The treatment — branded as Cabenuva and developed in collaboration with Janssen — was approved by Health Canada to suppress HIV in adults with stable […]

March 23, 2020 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Update: FDA Imposes No Penalties for Novartis Data Manipulation Scandal

Swiss and German Team to Develop Inhaled mRNA Coronavirus Treatment

Ipsen Resumes Phase III Testing for Rare Disease Drug and Abandons Pediatric Trial

Swiss Biopharma Launches Second Cancer Antibody Deal with Japanese Pharma Giant

Update: AM-Pharma Increases Acute Kidney Injury Phase III Funds to €163M

Evox Therapeutics Receives up to €800M from Takeda To Tackle Rare Diseases

Silence Therapeutics to Work with AstraZeneca in RNAi Deal Worth up to €3.6B

Novacyt Launches Two-Hour Coronavirus Test After FDA Approval

DBV Technologies’ Peanut Allergy Treatment Hits FDA Setback

Eli Lilly Sweetens AC Immune Alzheimer’s Treatment Deal by €38M

Vaccitech’s Prostate Cancer Vaccine Shows Promise in Phase II

ViiV Healthcare’s Monthly HIV Injection Gains First Approval in Canada

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!